Top Stories
Top Stories
Press Releases

BioMark Diagnostics, Inc. to present at the inaugural Small-Cap Stars Conference at the NASDAQ MarketSite on December 18, 2014

Globe Newswire

Vancouver, British Columbia, Dec. 16, 2014 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. ( "BioMark" or the "Company") (CSE: BUX,FSE:20B) is excited to announce that it will be presenting at theinaugural Small-Cap Stars Conference at theworld-famous NASDAQ MarketSite on December 18, 2014.

The event is a gathering of the brightest emerging growthNASDAQ-listed small-cap companies to present and network with anexclusive group of top-level institutional investors. Small-Cap Stars Conference is highlighted with akeynote presentation by legendary money manager and small-cappioneer Ken Fisher, CEO of Fisher Investments. There will also be aspecial guest presentation by Rock & Roll Hall of Famer GeneSimmons, a New York Times best-selling author and Master of BrandIdentity.

President and CEO of BioMark, Rashid Ahmed comments: "Theequities conference provides us with an outstanding venue to updateour investors and provides us with unparalleled access to major USinstitutions that understand the potential in the biopharma sectorfor Companies with advanced diagnostics solutions."

To learn more about BioMark Diagnostics, Inc., we encourage youto follow our Issuer Profile on, and to visit our website

The event is for an institutional audience only. Attendees willinclude: Hedge Funds, Family Offices, Portfolio Managers,Investment Banks & Venture Capitalists interested in small-capopportunities on the NASDAQ. One-on-One meetings are available forcompany management teams and qualified investors. designed this full-day event dedicated to creatingunparalleled discovery and exclusive networking sessions, includingour Holiday Cocktail party to cap off the conference. For moredetails on the conference, please visit

To learn more about or to become a member of ouronline financial community, please visit:

About BioMark DiagnosticsInc.

BioMark is developing proprietary, non-invasive, and accuratecancer diagnostic solutions which can help detect, monitor andassess treatment for cancer early and cost effectively. Thetechnology can also be used for measuring response to treatment andpotentially for serial monitoring for cancer survivors.

About, Inc. is an online financialpublication and social community for self-directed investors,public and private companies, market experts, and professionalservice providers across the global capital markets. Issuer Dashboard is an ideal SaaS platform toeffectively manage corporate communication and investor awarenesscampaigns, engage with market intermediaries and financialadvisors, and research industry peers. Registered members canleverage our market-leading commentary and content curation, aswell as our proprietary research tools, such as theSmall-Cap Stars, which spotlights promisinggrowth companies through our institutional-quality algorithms, andour robust do-it-yourself Equities Valuation Analysis(E.V.A.) research reports. Go to tobecome a member.

Further information about BioMark is available under its profileon the SEDAR website and on the CSE

Forward-Looking Information:

This press release may include forward-looking informationwithin the meaning of Canadian securities legislation, concerningthe business of BioMark.  Forward-looking information is basedon certain key expectations and assumptions made by the managementof BioMark. Although BioMark believes that the expectations andassumptions on which such forward-looking information is based arereasonable, undue reliance should not be placed on theforward-looking information because BioMark can give no assurancethat they will prove to be correct. Forward-looking statementscontained in this press release are made as of the date of thispress release. BioMark disclaims any intent or obligation to updatepublicly any forward-looking information, whether as a result ofnew information, future events or results or otherwise, other thanas required by applicable securities laws.

This news release does not constitute an offer to sell or asolicitation of an offer to buy any of the securities describedherein in the United States. The securities described herein havenot been and will not be registered under the United StatesSecurities Act of 1933, as amended, or any applicable securitieslaws or any state of the United States and may not be offered orsold in the United States or to the account or benefit of a personin the United States absent an exemption from the registrationrequirements.

CONTACT: For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.comSource:BioMark Diagnostics, Inc.

Related Tags